IL-1β has been reported to control tumor invasion, up-regulate the initiation and development of primary tumor, increase the aggressivity of luminal breast cancer cells, and increase IL-6 production through NF-κB pathway [250] leading to tumor growth and aggressiveness. This evidence concerns the gene NFKB1 and breast carcinoma.